Biochemistry of Parkinson's disease 28 years later: A critical review

[1]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[2]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .

[3]  O. Tenovuo,et al.  Substance P immunoreactivity in the post-mortem parkinsonian brain , 1984, Brain Research.

[4]  S. Mirra,et al.  The nucleus basalis of Meynert in neurological disease: A quantitative morphological study , 1985, Annals of neurology.

[5]  Y. Agid,et al.  Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.

[6]  Y. Agid,et al.  PROGRESSIVE SUPRANUCLEAR PALSY: LOSS OF STRIATAL DOPAMINE RECEPTORS DEMONSTRATED IN VIVO BY POSITRON TOMOGRAPHY , 1985, The Lancet.

[7]  Y. Stern,et al.  Intellectual changes in patients with MPTP‐induced parkinsonism , 1985, Neurology.

[8]  G. Koob,et al.  Neuroleptic-like distruption of the conditioned avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems , 1984, Brain Research.

[9]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[10]  Y. Agid,et al.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease , 1983, Brain Research.

[11]  F. Ikuta,et al.  Tyrosine hydroxylase protein in Lewy bodies of parkinsonian and senile brains , 1984, Journal of the Neurological Sciences.

[12]  F Lhermitte,et al.  Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions? , 1987, Neurology.

[13]  T. Crow,et al.  Dissociation of neuropeptide Y and somatostatin in Parkinson's disease , 1985, Brain Research.

[14]  Y. Agid,et al.  Dynorphin levels in parkinsonian patients: Leu5-enkephalin production from either proenkephalin A or prodynorphin in human brain , 1985, Brain Research.

[15]  S. Kish,et al.  Elevated γ‐aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: Correlation with striatal dopamine loss , 1986, Annals of neurology.

[16]  Y. Agid,et al.  Adrenergic receptors in Parkinson's disease , 1984, Brain Research.

[17]  Y. Agid,et al.  Nerve cell death in degenerative diseases of the central nervous system: clinical aspects. , 1987, Ciba Foundation symposium.

[18]  Y. Agid,et al.  Pathophysiology of L-dopa-induced abnormal involuntary movements. , 1985, Psychopharmacology. Supplementum.

[19]  Y. Agid,et al.  Microtopography of methionine-enkephalin, dopamine and noradrenaline in the ventral mesencephalon of human control and Parkinsonian brains , 1982, Brain Research.

[20]  S. Hunt,et al.  Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease , 1982, Brain Research.

[21]  H. Fibiger,et al.  Striatal GABAergic Neuronal Activity Is Not Reduced in Parkinson's Disease , 1983, Journal of neurochemistry.

[22]  D. Felten,et al.  Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults , 1986, Neuroscience Letters.

[23]  P. Mcgeer,et al.  ENZYMES ASSOCIATED WITH THE METABOLISM OF CATECHOLAMINES, ACETYLCHOLINE AND GABA IN HUMAN CONTROLS AND PATIENTS WITH PARKINSON'S DISEASE AND HUNTINGTON'S CHOREA , 1976, Journal of neurochemistry.

[24]  Y. Agid,et al.  CCK-8-immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients , 1982, Brain Research.

[25]  Y. Agid,et al.  Parkinson's disease: decreased density of 3H-imipramine and 3H- paroxetine binding sites in putamen , 1986, Neurology.

[26]  A. Graybiel,et al.  Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acetyltransferase in the human striatum , 1989, Neuroscience Letters.

[27]  W. Gibb,et al.  A comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease , 1988, Neurology.

[28]  Y. Agid,et al.  Somatostatin concentrations and binding sites in human frontal cortex are differentially affected in Parkinson's disease associated dementia and in progressive supranuclear palsy , 1988, Journal of the Neurological Sciences.

[29]  Y Agid,et al.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. , 1984, European journal of pharmacology.

[30]  D. Price,et al.  Reductions in corticotropin releasing factor‐like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy , 1987, Neurology.

[31]  C. Duyckaerts,et al.  Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients , 1986, Brain Research.

[32]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Yates,et al.  PATHOLOGICAL BASIS FOR NEUROTRANSMITTER CHANGES IN PARKINSON'S DISEASE , 1983, Neuropathology and applied neurobiology.

[34]  B. Burns,et al.  Parkinson's disease--a random process. , 1967, Canadian Medical Association journal.

[35]  Y. Agid,et al.  Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease , 1985, Annals of neurology.

[36]  O. Hornykiewicz,et al.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease , 1978, Nature.

[37]  Yves Agid,et al.  A subcortico-cortical cholinergic system is affected in Parkinson's disease , 1983, Brain Research.

[38]  O. Hornykiewicz.  Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.

[39]  Y. Agid,et al.  Parkinson's disease affects differently Met5- and Leu5-enkephalin in the human brain , 1983, Brain Research.

[40]  R. Duvoisin,et al.  Response of patients with postencephalitic Parkinsonism to levodopa 1 , 1972, Journal of neurology, neurosurgery, and psychiatry.

[41]  Y. Agid,et al.  Regional distribution of μ, δ and κ opioid receptors in human brains from controls and parkinsonian subjects , 1987, Brain Research.

[42]  D L Price,et al.  Aminergic systems in Alzheimer's disease and Parkinson's disease , 1987, Annals of neurology.

[43]  E. Hirsch,et al.  Dopaminergic and cholinergic lesions in progressive supranuclear palsy , 1985, Annals of neurology.

[44]  B. Scatton,et al.  Parkinson's disease and dementia , 1987, Neurology.

[45]  K. Jellinger,et al.  CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies. , 1978, Journal of neural transmission. Supplementum.

[46]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[47]  D L Price,et al.  Parkinson's disease , 1985, Neurology.

[48]  J. Langston,et al.  Older dopaminergic neurons do not recover from the effects of MPTP , 1987, Neuropharmacology.

[49]  Y. Agid,et al.  Peptides and Parkinson's disease , 1985, Trends in Neurosciences.

[50]  D. Price,et al.  Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease , 1988, Neurology.

[51]  Y. Agid,et al.  Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index. , 1985, Brain : a journal of neurology.

[52]  U. Roessmann,et al.  Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations , 1980, Annals of neurology.

[53]  D L Price,et al.  Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.

[54]  M. Yahr,et al.  Measurements of visual evoked potentials in Parkinson's disease. , 1978, Brain : a journal of neurology.

[55]  P. Riekkinen,et al.  Brain glutamic acid decarboxylase activity in Parkinson's disease. , 1974, European neurology.

[56]  C. Bulens,et al.  Effect of levodopa treatment on contrast sensitivity in Parkinson's disease , 1987, Annals of Neurology.

[57]  Y. Agid,et al.  Cortical vasoactive intestinal peptide in relation to dementia in Parkinson's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[58]  A. Graybiel,et al.  Differences in tyrosine hydroxylase-like immunoreactivity characterize the mesostriatal innervation of striosomes and extrastriosomal matrix at maturity. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[59]  S. Carmichael,et al.  Decreased catecholamines in the adrenal medulla of patients with parkinsonism. , 1988, The New England journal of medicine.

[60]  V. Koskinen,et al.  GABA receptor binding in the parkinsonian brain. , 1978, Life sciences.

[61]  D. Scherman,et al.  Noradrenaline, adrenaline and tyrosine hydroxylase in adrenal medulla from parkinsonian patients. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[62]  J. Rinne,et al.  Brain muscarinic receptors in senile dementia , 1985, Brain Research.

[63]  K. Jellinger,et al.  The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[64]  E. Perry,et al.  Cortical serotonin-S2 receptor binding abnormalities in patients with Alzheimer's disease: Comparisons with Parkinson's disease , 1984, Neuroscience Letters.

[65]  Y. Agid,et al.  [3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. , 1988, European journal of pharmacology.

[66]  Y. Agid,et al.  Thyrotropin releasing hormone content is unchanged in brains of patients with Parkinson disease , 1983, Neuropeptides.

[67]  L. Ronnevi,et al.  Increased fragility of erythrocytes from amyotrophic lateral sclerosis (ALS) patients provoked by mechanical stress , 1984, Acta neurologica Scandinavica.

[68]  Y. Agid,et al.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia , 1982, Brain Research.

[69]  E. Perry,et al.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[70]  J. Langston,et al.  Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) , 1985, Neurology.

[71]  E. Perry,et al.  CORTICAL CHOLINERGIC DEFICIT IN MENTALLY IMPAIRED PARKINSONIAN PATIENTS , 1983, The Lancet.

[72]  P. Bédard,et al.  The rubro-olivo-cerebello-rubral loop and postural tremor in the monkey. , 1970, Journal of the neurological sciences.

[73]  Y. Agid,et al.  Enkephalinergic Markers in Substantia Nigra and Caudate Nucleus from Parkinsonian Subjects , 1984, Journal of neurochemistry.

[74]  U. Rinne,et al.  Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. , 1973, Archives of neurology.

[75]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[76]  Y. Agid,et al.  Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains , 1983, Brain Research.

[77]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[78]  C. Marsden,et al.  Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[79]  Y. Agid,et al.  Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease , 1986, Brain Research.

[80]  Y Agid,et al.  Is the mesocortical dopaminergic system involved in Parkinson disease? , 1980, Neurology.

[81]  F. Checler,et al.  Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects. , 1984, Biochemical and biophysical research communications.

[82]  T. Perry,et al.  Brain amino acids and glutathione in progressive supranuclear palsy , 1988, Neurology.

[83]  Y. Agid,et al.  Somatostatin and dementia in Parkinson's disease , 1983, Brain Research.

[84]  Niall Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[85]  I. Nakano,et al.  Parhnson’s Disease: Neuron Loss in the Nucleus Basah Without Concomitant Alzheimer’s Disease , 2004 .

[86]  Y. Agid,et al.  D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy , 1988, Journal of the Neurological Sciences.

[87]  Y. Naum,et al.  Growth of Pulmonary Alveolar Macrophages in vitro , 1973, Nature.

[88]  F Lhermitte,et al.  Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? , 1989, Journal of neurology, neurosurgery, and psychiatry.

[89]  A M Graybiel,et al.  Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Y. Agid,et al.  Dopamine D‐1 Receptor and Cyclic AMP‐Dependent Phosphorylation in Parkinson's Disease , 1987, Journal of neurochemistry.

[91]  H. Chapel,et al.  CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN , 1989, The Lancet.

[92]  O. Hornykiewicz.  Parkinson's disease and its chemotherapy. , 1975, Biochemical pharmacology.

[93]  Y. Agid,et al.  Biochemistry of the hypothalamus in Parkinson's disease , 1984, Neurology.

[94]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[95]  P. Yates,et al.  The pathology of the human locus ceruleus. , 1983, Clinical neuropathology.

[96]  P. Mcgeer,et al.  Aging and extrapyramidal function. , 1977, Archives of neurology.

[97]  Y. Agid,et al.  Decrease of serotonin‐S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy , 1988, Movement disorders : official journal of the Movement Disorder Society.